PMID- 35338947
OWN - NLM
STAT- MEDLINE
DCOM- 20220510
LR  - 20220511
IS  - 1873-3360 (Electronic)
IS  - 0306-4530 (Linking)
VI  - 140
DP  - 2022 Jun
TI  - Diabetes, antidiabetic medications and risk of depression - A population-based 
      cohort and nested case-control study.
PG  - 105715
LID - S0306-4530(22)00056-7 [pii]
LID - 10.1016/j.psyneuen.2022.105715 [doi]
AB  - OBJECTIVE: Diabetes type 2 is associated with depression, but the impact of 
      antidiabetic drugs is not clear. The objective was to analyze the association 
      between diabetes type 2, antidiabetic drugs, and depression. METHODS: This 
      register-based study included 116.699 patients with diabetes type 2 diagnosed 
      from 2000 to 2012 and an age, gender, and municipality matched reference group of 
      116.008 individuals without diabetes. All participants were followed for a 
      diagnosis of depression or prescription of antidepressant medication. Based on 
      this, a case-control study was nested within the cohort, using risk set sampling. 
      Antidiabetic medication was categorized into insulin, metformin, sulfonylureas 
      and glinides combined, glitazones, dipeptidyl peptidase 4 (DPP4) inhibitors, 
      glucagon-like peptide 1 (GLP1) analogs, sodium-glucose transport protein 2 
      (SGLT2) inhibitors and acarbose. The association between diabetes and depression 
      was analyzed using Cox proportional hazards regression, whereas conditional 
      logistic regression was used to analyze the association between use of 
      antidiabetic drugs and depression. RESULTS: Patients with diabetes had higher 
      risk of depression compared to individuals without diabetes (hazard ratio 1.14 
      (95% confidence interval 1.14-1.15)). Low doses of metformin, DPP4 inhibitors, 
      GLP1 analogs, and SGLT2 inhibitors were associated with lower risk of depression 
      in patients with diabetes compared to non-users, with the lowest risk for 
      sodium-glucose transport protein 2 inhibitor users (odds ratio 0.55 (0.44-0.70)). 
      Use of insulin, sulfonylurea and high doses of metformin were associated with 
      higher risk of depression. CONCLUSION: Patients with diabetes had increased risk 
      of depression. However, users of specific antidiabetic drugs had lower risk of 
      depression compared to non-users.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Wium-Andersen, Ida Kim
AU  - Wium-Andersen IK
AD  - Psychiatric Center Copenhagen, Region Hovedstadens Psykiatri, Edel Sauntes Alle 
      10, 2100 Copenhagen, Denmark. Electronic address: 
      Ida.kim.wiumandersen@regionh.dk.
FAU - Osler, Merete
AU  - Osler M
AD  - Center for Clinical Research and Prevention, Bispebjerg-Frederiksberg University 
      Hospital, Nordre Fasanvej 57, 2000 Frederiksberg, Denmark; Section of 
      Epidemiology, Department of Public Health, University of Copenhagen, Oster 
      Farimagsgade 5, 1014 Copenhagen, Denmark.
FAU - Jorgensen, Martin Balslev
AU  - Jorgensen MB
AD  - Psychiatric Center Copenhagen, Region Hovedstadens Psykiatri, Edel Sauntes Alle 
      10, 2100 Copenhagen, Denmark.
FAU - Rungby, Jorgen
AU  - Rungby J
AD  - Department of Endocrinology, Bispebjerg-Frederiksberg University Hospital, 
      Bispebjerg bakke 23, 2400 Copenhagen, Denmark; Copenhagen Center for 
      Translational Research, Bispebjerg-Frederiksberg University hospital, Bispebjerg 
      Bakke 23, 2400 Copenhagen, Denmark.
FAU - Wium-Andersen, Marie Kim
AU  - Wium-Andersen MK
AD  - Center for Clinical Research and Prevention, Bispebjerg-Frederiksberg University 
      Hospital, Nordre Fasanvej 57, 2000 Frederiksberg, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220315
PL  - England
TA  - Psychoneuroendocrinology
JT  - Psychoneuroendocrinology
JID - 7612148
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Case-Control Studies
MH  - Depression/drug therapy
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - Glucagon-Like Peptide 1
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Insulin/therapeutic use
MH  - *Metformin/adverse effects
EDAT- 2022/03/27 06:00
MHDA- 2022/05/11 06:00
CRDT- 2022/03/26 20:08
PHST- 2021/08/20 00:00 [received]
PHST- 2022/01/26 00:00 [revised]
PHST- 2022/03/07 00:00 [accepted]
PHST- 2022/03/27 06:00 [pubmed]
PHST- 2022/05/11 06:00 [medline]
PHST- 2022/03/26 20:08 [entrez]
AID - S0306-4530(22)00056-7 [pii]
AID - 10.1016/j.psyneuen.2022.105715 [doi]
PST - ppublish
SO  - Psychoneuroendocrinology. 2022 Jun;140:105715. doi: 
      10.1016/j.psyneuen.2022.105715. Epub 2022 Mar 15.